Benzinga | Aug 4, 2021 07:43AM EDT

EyePoint Pharmaceuticals Q2 EPS $(0.35) Beats $(0.43) Estimate, Sales $8.70M Miss $9.13M Estimate

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.43) by 18.6 percent. This is a 250 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $8.70 million which missed the analyst consensus estimate of $9.13 million by 4.71 percent. This is a 0.78 percent increase over sales of $8.63 million the same period last year.